Lawyers representing the state plan to show that Connecticut-based Purdue Pharma kept doctors, pharmacists, and patients uninformed about the drug's addictive qualities so it could sell more pills.

When Purdue Pharma began selling OxyContin, which contains more oxycodone than other commonly misused painkillers, the company said users were unlikely to get high from the drug because it was time-released over a 12-hour period.

However, many drug users discovered that they could crush the pill and ingest a tablet's entire oxycodone dose at once. In West Virginia, nearly half of the individuals being treated for drug addiction listed OxyContin as their drug of choice.

Lawyers for Purdue Pharma plan to counter the state's arguments by showing that the drug has provided relief to cancer patients and other chronic-pain sufferers.

"It is safe and effective when used as intended, and that is what is intended by Purdue," said Timbera Wilcox, one of the company's lawyers.

Although the state has not asked for a specific monetary award, it could equal or exceed the $30.5 million that various state agencies have spent on OxyContin between 1996, when Purdue Pharma first started shipping OxyContin to West Virginia pharmacies, and 2003.

McDowell Circuit Judge Booker Stephens will oversee the trial.

COMMENTS ON THIS ARTICLE:

Your Turn! Post a public comment (read guidelines):

Name:
Comment: (limit 200 words)
Enter this word (help):	Change

GUIDELINES: 
To keep this feature useful for all, please:

1. Keep it clean, courteous, and on-topic. Comments are meant for thoughtful discussion of the article published above.
   
   
2. Do not post promotional links to organizations, products or services, or personal requests for assistance (get help).
   
   
3. Proof your comments carefully, use good spelling and punctuation, and don't use ALL CAPS. Comments are published immediately and cannot be edited.

Deceptive, slanderous and commercially-motivated posts are prohibited. We reserve the right to remove comments not conforming to these guidelines. (Report a comment).

Have questions or feedback? Contact us.